Iterum Therapeutics plc — Director's Dealing 2018

May 30, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Iterum Therapeutics plc (ITRM)
CIK: 0001659323
Period of Report: 2018-05-30

Reporting Person: Ahrens Brenton Karl (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-05-30	Ordinary Shares	C	721408	—	Acquired	721408	Indirect
2018-05-30	Ordinary Shares	C	275446	—	Acquired	996854	Indirect
2018-05-30	Ordinary Shares	C	229660	—	Acquired	1226514	Indirect
2018-05-30	Ordinary Shares	P	506656	$13.00	Acquired	1733170	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-05-30	Series A Preferred Shares	$	C	721408	Disposed		Ordinary Shares (721408)	Indirect
2018-05-30	Series B-1 Preferred Shares	$	C	275446	Disposed		Ordinary Shares (275446)	Indirect
2018-05-30	Series B-2 Preferred Shares	$	C	229660	Disposed		Ordinary Shares (229660)	Indirect

Footnotes

F1: The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer and had no expiration date.

F2: These shares are held directly by Canaan X L.P. (the "Canaan Fund"). The sole general partner of the Canaan Fund is Canaan Partners X LLC ("Canaan X", and together with the Canaan Fund, the "Canaan Entities"). Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan X, collectively. The Reporting Person, a manager and member of Canaan X, serves as the representative of the Canaan Entities on the Issuer's board of directors. The Reporting Person disclaims Section 16 beneficial ownership in the securities held by the Canaan Entities, except to the extent of his pecuniary interest therein, if any, in such securities by virtue of the limited liability company interests he owns in Canaan X.

F3: The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer and had no expiration date.

F4: The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer and had no expiration date.